Astera Labs heads into Q1 earnings with strong AI-driven growth and rising revenues, but high valuation, margin pressure, and stiff competition cloud the outlook.
Astera Labs heads into Q1 earnings with strong AI-driven growth and rising revenues, but high valuation, margin pressure, and stiff competition cloud the outlook.
Meta just reported one of its strongest quarters in years. Revenue up 33%. Earnings beat. Daily active users at 3.56 billion, according to Meta IR. By almost every measure, the business is performing. The stock still fell 10%. And the analyst who had been one of Meta's biggest bulls on Wall Street ...
Meta just reported one of its strongest quarters in years. Revenue up 33%. Earnings beat. Daily active users at 3.56 billion, according to Meta IR. By almost every measure, the business is performing. The stock still fell 10%. And the analyst who had been one of Meta's biggest bulls on Wall Street ...
Shares of Robinhood Markets (NASDAQ: HOOD) have fallen 11.8% this week, according to data from S&P Global Market Intelligence . The digital brokerage keeps growing its user base and deposits, but saw a huge decrease in cryptocurrency revenue , which has Wall Street spooked. Here's why Robinhood stock was falling this week, and whether investors should consider buying the dip today. Robinhood relea...
Shares of Robinhood Markets (NASDAQ: HOOD) have fallen 11.8% this week, according to data from S&P Global Market Intelligence . The digital brokerage keeps growing its user base and deposits, but saw a huge decrease in cryptocurrency revenue , which has Wall Street spooked. Here's why Robinhood stock was falling this week, and whether investors should consider buying the dip today. Robinhood released its Q1 2026 earnings on April 28th. Revenue was up 15% year-over-year to $1.07 billion, while net income only grew 3% to $346 million. Continue reading
Where's the Trump phone? We're going to keep talking about it every week . We've reached out, as usual, to ask about the Trump phone's whereabouts. This time we've discovered a little more evidence that the phone is on its way to a release. Trump Mobile's T1 Phone has just passed another milestone on its slow road to release. The phone has received the little-known PTCRB certification, a first ste...
Where's the Trump phone? We're going to keep talking about it every week . We've reached out, as usual, to ask about the Trump phone's whereabouts. This time we've discovered a little more evidence that the phone is on its way to a release. Trump Mobile's T1 Phone has just passed another milestone on its slow road to release. The phone has received the little-known PTCRB certification, a first step toward being certified to work on major networks and be issued with IMEI numbers. You probably haven't heard of PTCRB certification - I hadn't until recently. It doesn't come up very often. It's the North American certification process for smartp … Read the full story at The Verge.
Hello and welcome to the newsletter, a grab bag of daily content from the Odd Lots universe. Sometimes it’s us, Joe Weisenthal and Tracy Alloway, bringing you our thoughts on the most recent developments in markets, finance and the economy. And sometimes it’s contributions from our network of expert guests and sources. Whatever it is, we promise it will always be interesting. If you like chatting ...
Hello and welcome to the newsletter, a grab bag of daily content from the Odd Lots universe. Sometimes it’s us, Joe Weisenthal and Tracy Alloway, bringing you our thoughts on the most recent developments in markets, finance and the economy. And sometimes it’s contributions from our network of expert guests and sources. Whatever it is, we promise it will always be interesting. If you like chatting with us, check out the Odd Lots Discord , where you can hang out and talk with us and with other listeners 24/7. Oh and before you read on, just as a reminder, on May 28, we’re doing a live Odd Lots show in New York City. Tickets are selling fast, but there are still some available. Get your tickets now here . What Joe is thinking about today I debated for a little while whether the title of today’s newsletter was too hyperbolic or clickbait-y. But I don’t think so. I just got back from four nights in Madrid (Tracy and I were participating in the Bloomberg CityLab conference, so expect some episodes from that in the near future) and the internet feels like a different place than it was before I left. Before I explain, here’s a little background. I continue to think that one of the best things I’ve done to get a better sense of where the internet is going has been using Claude Code and building a few things. I’m not saying that I’ve had any special breakthroughs or like that, but it’s been great for sharpening some of my intuitions about the existing architecture of the internet, and how it will inevitably change in the age of AI. However, before I explain that , let me give you an update on one of my projects. Earlier in the year, I wrote about and built Fedlock , which is an attempt to measure central bank policy tilt using LLMs. I won’t get into the whole project, but the basic gist is simple. I have a corpus of (almost) every monetary policy speech delivered by an FOMC member since 1995 which I then anonymized. Next, I show two different speeches side by side to the AI (...
hapabapa/iStock Editorial via Getty Images In the world of biotech, no news is only a little better than bad news, as institutional investor moves are often timed with major upcoming pipeline events. For Alnylam Pharmaceuticals ( ALNY ), 2026 is likely to be a relatively quiet year, giving analysts and investors more time to fixate on the quarterly gyrations of the TTR amyloidosis market and favor...
hapabapa/iStock Editorial via Getty Images In the world of biotech, no news is only a little better than bad news, as institutional investor moves are often timed with major upcoming pipeline events. For Alnylam Pharmaceuticals ( ALNY ), 2026 is likely to be a relatively quiet year, giving analysts and investors more time to fixate on the quarterly gyrations of the TTR amyloidosis market and favor names with more thesis-changing clinical updates on the way. Alnylam shares are down slightly since my last update , and what bearish chatter there is largely revolves around the ongoing dynamics of the TTR amyloidosis market and concerns about whether the company can maintain its momentum here. I believe Alnylam remains well-placed not only in the evolving TTR space but also as a platform/franchise biotech capable of reliably generating high-value clinical assets year after year. Clinical and product updates later in the year could drive a little more interest, but for the time being investors are going to have to be patient with a name that I believe offers attractive upside but a lot of attention-grabbing news flow in the near term. Q1 Results Show The TTR Franchise Is Still On Track As I discussed in the last couple of Alnylam articles, the first quarter of 2026 was going to be a little more challenging for TTR franchise revenue ( Onpattro and Amvuttra ) given insurance reauthorizations, a price cut in Germany, and some inventory dynamics. Exiting the quarter, it looks like the business is on track for ongoing growth. To be clear, analysts were fretting about a franchise that still managed to generate 150% year-over-year and 6% quarter-over-quarter growth in a “bad” or “tough” quarter. Amvuttra continues to be a strong engine of growth for the franchise, with growing front-line share and strong ongoing usage as a second-line therapy (typically behind Pfizer’s ( PFE ) tafamidis ( Vyndamax ). Overall net product revenue rose 117% in constant currency terms, with the TTR ...
Generac Holdings (NYSE: GNRC) stock jumped this week after reporting quarterly earnings and boosting its full-year sales forecast. Shares were about 17% above last week's close as of Friday at noon, according to data provided by S&P Global Market Intelligence . A sluggish housing market isn't slowing Generac's growth. That's because the company is now seeing strength from the expanding data center...
Generac Holdings (NYSE: GNRC) stock jumped this week after reporting quarterly earnings and boosting its full-year sales forecast. Shares were about 17% above last week's close as of Friday at noon, according to data provided by S&P Global Market Intelligence . A sluggish housing market isn't slowing Generac's growth. That's because the company is now seeing strength from the expanding data center construction market. Continue reading